All In Biotech

NDA 008578 · Tilde Sciences

Daraprim

Pyrimethamine · Oral · Dihydrofolate Reductase Inhibitor Antimalarial

NovelPriority review

Last checked: Nov 20, 2026Latest source record: Jun 21, 2017 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

1953

Jan 23, 1953

Approved uses

1

Original approval plus efficacy supplements

Registered trials

195

69 Phase 3, 1 recruiting

FAERS reports

1,270

980 serious, 221 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Dec 7, 2023.

INDICATIONS AND USAGE Treatment of Toxoplasmosis: DARAPRIM is indicated for the treatment of toxoplasmosis when used conjointly with a sulfonamide, since synergism exists with this combination.

Therapeutic areas: Infectious disease and vaccines

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • Jan 23, 1953 Original approval · Type 1 - New Molecular Entity · priority review Label
1 products under this application
  • DARAPRIM · PYRIMETHAMINE 25MG · TABLET, ORAL · Prescription · TE AB

Clinical trials

Interventional ClinicalTrials.gov studies with "Pyrimethamine" as an intervention, any sponsor and status, largest first.

All 195 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • off label use164
  • nausea134
  • vomiting101
  • pancytopenia91
  • drug ineffective73
  • neutropenia72
  • pyrexia64
  • headache63
  • death50
  • dizziness50
  • acute kidney injury49
  • rash49

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
200422
200516
200613
200716
200823
200927
201024
201119
201218
201321
201429
201526
201677
201785
2018128
2019103
2020136
2021107
2022125
202379
202472
202557
202647

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 975 on PubMed

Sponsor: Tilde Sciences

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.